Methods to induce targeted protein degradation through bifunctional molecules

A compound, which is:

• or a stereoisomer or pharmaceutically acceptable salt thereof, wherein:
• is
• Y is a bond, (CH2)1-6, (CH2)0-6—O, (CH2)0-6—C(O)NR2′, (CH2)0-6—NR2′C(O), (CH2)0-6—NH, or (CH2)0-6—NR2;
• X is C(O) or C(R3)2;
• X1-X2 is C(R3)═N or C(R3)2—C(R3)2;
• each R1 is independently halogen, OH, C1-C6 alkyl, or C1-C6 alkoxy;
• R2 is C1-C6 alkyl, C(O)—C1-C6 alkyl, or C(O)—C3-C6 cycloalkyl;
• R2′ is H or C1-C6 alkyl;
• each R3 is independently H or C1-C3 alkyl;
• each R3′ is independently C1-C3 alkyl;
• each R4 is independently H or C1-C3 alkyl;
• or two R4, together with the carbon atom to which they are attached, form C(O);
• R5 is H, deuterium, C1-C3 alkyl, F, or Cl;
• m is 0, 1, 2, or 3;
• n is 0;
• the Linker is a group that covalently binds to the Targeting Ligand and Y;
• and
• wherein the Targeting Ligand is:
• wherein:
• T7 is CH2 or CH2CH2;
• Rg1 is C(O)Rg5 or (CH2)1-3Rg6;
• nn10 is 0, 1, 2, or 3;
• nn11 is 0, 1, 2, or 3;
• each Rg2 is independently C1-C3 alkyl, C1-C3 alkoxy, CN, or halogen;
• Rg3 is C(O)NRg4L, OL, NRg4L, L, O—(CH2)1-3—C(O)NRg4L, or NHC(O)—(CH2)1-3—C(O)NRg4L;
• Rg4 is H or C1-C3 alkyl;
• Rg5 is C1-6 alkyl;
• Rg6 is phenyl optionally substituted with C1-C3 alkyl, C1-C3 alkoxy, CN, or halogen;
• and
• L is the attachment point to the linker.